Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report

• Main Authors: Shun Matsuura, Keisuke Morikawa, Yutaro Ito, Namio Kagoo, Tsutomu Kubota, Koshiro Ichijo, Eisuke Mochizuki, Masahiro Uehara, Masanori Harada, Masaru Tsukui, Naoki Koshimizu
• Format: Article
• Language: English
• Published: Elsevier 2020-01-01
• Series: Respiratory Medicine Case Reports
• Subjects: EGFR; Exon 20 insertion; Durvalumab; Non-small-cell lung cancer
• Online Access: http://www.sciencedirect.com/science/article/pii/S2213007120304500

Epidermal growth factor receptor (EGFR) exon 20 insertion is not associated with sensitivity to EGFR tyrosine kinase inhibitors and chemotherapy. Here, we report the case of a 41-year-old man who presented a right lower lobe nodule and mediastinal lymph node enlargement diagnosed as EGFR exon 20 insertion adenocarcinoma with high-expression programmed cell death ligand 1 (PD-L1). He showed stable disease to chemoradiation treatment at the primary tumor site. However, durvalumab treatment has good response. Non-small cell lung cancer with EGFR exon 20 insertion and high PD-L1 expression may be treated with immunotherapy exposure.